Bronte Capital Management Pty Ltd.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1471085
Bondi Junction, C3
Position in ALNY
as of Mar 31, 2026
· filed Apr 27, 2026
Position Value
$12,323,253
-$3,131,016 QoQ
Shares Held
37,245
-4.2% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
1.54%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bronte Capital Management Pty Ltd. holds $160,316,289 across 13 Biotechnology names. ALNY ranks #3 (7.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
172,787 | $133,502,147 | |
| 2 | NKTR |
Nektar Therapeutics
|
198,256 | $14,264,519 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
37,245 | $12,323,253 | |
| 4 | ALEC |
Alector, Inc.
|
19,282 | $41,456 | |
| 5 | CHRS |
Coherus Oncology, Inc.
|
19,282 | $32,586 | |
| 6 | CRBU |
Caribou Biosciences, Inc.
|
15,627 | $29,691 | |
| 7 | FATE |
Fate Therapeutics Inc
|
22,853 | $27,423 | |
| 8 | CCCC |
C4 Therapeutics, Inc.
|
10,033 | $26,386 |
All Filings in ALNY
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $12,323,253 | 37,245 | Shares | Sole | 2026-04-27 | |
| 2025-12-31 | $15,454,269 | 38,864 | Shares | Sole | 2026-02-03 | |
| 2025-09-30 | $15,948,144 | 34,974 | Shares | Sole | 2025-11-05 | |
| No filing history on record for this holder in this stock. | ||||||